GLN-POSACONAZOLE 100 MG
POSACONAZOLE : 100 MG · DIN 02542021 · GLENMARK PHARMACEUTICALS CANADA INC.
Health Canada status: MARKETED
What is GLN-POSACONAZOLE?
GLN-POSACONAZOLE 100 MG contains POSACONAZOLE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02542021, held by GLENMARK PHARMACEUTICALS CANADA INC., supplied as TABLET (DELAYED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 04-Oct-2023. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02542021 |
|---|---|
| Brand name | GLN-POSACONAZOLE |
| Generic / active ingredient | POSACONAZOLE : 100 MG |
| Manufacturer | GLENMARK PHARMACEUTICALS CANADA INC. |
| Strength | 100 MG |
| Dosage form | TABLET (DELAYED-RELEASE) |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J02AC04 POSACONAZOLE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 04-Oct-2023 |
What can be used instead?
Other Canadian products sharing ATC code J02AC04 POSACONAZOLE. 8 of 9 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP POSACONAZOLE | 40 MG | SUSPENSION | JAMP PHARMA CORPORATION | MARKETED | DIN 02530333 |
| MINT-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | MINT PHARMACEUTICALS INC | MARKETED | DIN 02544644 |
| POSANOL | 100 MG | TABLET (DELAYED-RELEASE) | MERCK CANADA INC | MARKETED | DIN 02424622 |
| POSANOL | 200 MG / 5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | DIN 02293404 |
| POSANOL | 300 MG / 16.7 ML | SOLUTION | MERCK CANADA INC | MARKETED | DIN 02432676 |
| SANDOZ POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02496259 |
| TARO-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | TARO PHARMACEUTICALS INC | MARKETED | DIN 02543311 |
| APO-POSACONAZOLE | 100 MG | TABLET (DELAYED-RELEASE) | APOTEX INC | APPROVED | DIN 02511878 |
Who else supplies POSACONAZOLE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. POSACONAZOLE appears in 106 registered pack listings across 12 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.